Subnanomolar indazole-5-carboxamide inhibitors of monoamine oxidase B (MAO-B) continued: indications of iron binding, experimental evidence for optimised solubility and brain penetration
Pharmacological and physicochemical studies of N-unsubstituted indazole-5-carboxamides (subclass I) and their structurally optimised N1-methylated analogues (subclass II), initially developed as drug and radioligand candidates for the treatment and diagnosis of Parkinson’s disease (PD), are presente...
Main Authors: | Nikolay T. Tzvetkov, Liudmil Antonov |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-01-01
|
Series: | Journal of Enzyme Inhibition and Medicinal Chemistry |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/14756366.2017.1344980 |
Similar Items
-
Dual-target anti-Alzheimer’s disease agents with both iron ion chelating and monoamine oxidase-B inhibitory activity
by: Zhisheng Mi, et al.
Published: (2019-01-01) -
Three Dimensional Pharmacophore Modelling of Monoamine oxidase-A (MAO-A) inhibitors
by: Swatantra K. Jain, et al.
Published: (2007-09-01) -
Inhibitory effects of agmatine on monoamine oxidase (MAO) activity: Reconciling the discrepancies
by: Mancinelli Loretta, et al.
Published: (2018-04-01) -
Monoamine Oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature Analysis
by: Andy Wai Kan Yeung, et al.
Published: (2019-05-01) -
Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease
by: Shoko Kakinuma, et al.
Published: (2020-06-01)